News & Updates

Adjunctive intra-arterial lytics bounce back in ANGEL-TNK, PEARL trials

07 Mar 2025 by

Two trials presented at ISC 2025 support intra-arterial thrombolysis as an adjunct to stroke thrombectomy in patients with large-vessel occlusions (LVOs).

Adjunctive intra-arterial lytics bounce back in ANGEL-TNK, PEARL trials

07 Mar 2025

Foetal malformation risk high in ART-conceived pregnancies of women with epilepsy

06 Mar 2025

Conception via assisted reproductive technology (ART) carries an increased risk of foetal malformation among women with epilepsy, according to a study.

Foetal malformation risk high in ART-conceived pregnancies of women with epilepsy

06 Mar 2025

COVID-19 ups AIBD risk, but vaccination helps

06 Mar 2025 by

Individuals with COVID-19 infection are at higher risk of autoimmune blistering disease (AIBD), but vaccination helps reduce such risk, suggests a study.

COVID-19 ups AIBD risk, but vaccination helps

06 Mar 2025

Two- vs one-bag method: Which works best for DKA treatment?

06 Mar 2025

Implementation of the two-bag method for the management of diabetic ketoacidosis (DKA) has improved safety and efficacy outcomes when compared with the one-bag method, according to a study.

Two- vs one-bag method: Which works best for DKA treatment?

06 Mar 2025

Tislelizumab a new Tx alternative for very high-risk bladder cancer?

06 Mar 2025 by

In the phase II pilot TRUCE-02 trial, tislelizumab plus low-dose nab-paclitaxel shows promising clinical antitumour activity and is well tolerated in patients with extensive very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC) who are ineligible for or decline radical cystectomy (RC).

Tislelizumab a new Tx alternative for very high-risk bladder cancer?

06 Mar 2025

Immune changes, persistent spike protein seen in people with PVS

06 Mar 2025 by

People with post-vaccination syndrome (PVS), a rare condition following receipt of COVID-19 jabs, exhibit distinct immunological patterns, including the reappearance of the dormant Epstein-Barr virus (EBV) and persistence of SARS-CoV-2 spike protein in the blood, according to new research.

Immune changes, persistent spike protein seen in people with PVS

06 Mar 2025

Shorter duration, larger lesion predict treatment failure with 5-FU 5% cream

05 Mar 2025

Treatment with 5-fluorouracil (5-FU) 5% cream tends to end in failure with shorter treatment duration and larger lesion size in patients with squamous cell carcinoma in situ (SCCis), a study has shown.

Shorter duration, larger lesion predict treatment failure with 5-FU 5% cream

05 Mar 2025

EV-302 2-year updates: EV+P maintains transformative benefit in bladder cancer

05 Mar 2025 by

The updated analysis of the phase III EV-302 trial continues to show the benefit of front-line enfortumab vedotin plus pembrolizumab (EV+P) compared with chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

EV-302 2-year updates: EV+P maintains transformative benefit in bladder cancer

05 Mar 2025

No cardiovascular signal with anti-CGRP mAbs for migraine

05 Mar 2025

Migraine treatment with monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor does not appear to contribute to increased risk of cardiovascular disease (CVD) compared with onabotulinumtoxinA in adults, including those who are older and with disability, according to a retrospective cohort study.

No cardiovascular signal with anti-CGRP mAbs for migraine

05 Mar 2025

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

05 Mar 2025 by

The combination of nivolumab and ipilimumab (NIVO + IPI) significantly improves overall survival (OS) and objective response rate (ORR) compared with lenvatinib or sorafenib (LEN/SOR) in the first-line setting for patients with unresectable hepatocellular carcinoma (uHCC), based on the CheckMate 9DW expanded analyses presented at ASCO GI 2025.

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

05 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

Adjunctive intra-arterial lytics bounce back in ANGEL-TNK, PEARL trials

Adjunctive intra-arterial lytics bounce back in ANGEL-TNK, PEARL trials

Foetal malformation risk high in ART-conceived pregnancies of women with epilepsy

Foetal malformation risk high in ART-conceived pregnancies of women with epilepsy

COVID-19 ups AIBD risk, but vaccination helps

COVID-19 ups AIBD risk, but vaccination helps

Two- vs one-bag method: Which works best for DKA treatment?

Two- vs one-bag method: Which works best for DKA treatment?

Tislelizumab a new Tx alternative for very high-risk bladder cancer?

Tislelizumab a new Tx alternative for very high-risk bladder cancer?

Immune changes, persistent spike protein seen in people with PVS

Immune changes, persistent spike protein seen in people with PVS

Shorter duration, larger lesion predict treatment failure with 5-FU 5% cream

Shorter duration, larger lesion predict treatment failure with 5-FU 5% cream

EV-302 2-year updates: EV+P maintains transformative benefit in bladder cancer

EV-302 2-year updates: EV+P maintains transformative benefit in bladder cancer

No cardiovascular signal with anti-CGRP mAbs for migraine

No cardiovascular signal with anti-CGRP mAbs for migraine

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC